Krystal Biotech to Participate in Upcoming Investor Conferences
March 29, 2021 16:30 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two...
Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications
March 24, 2021 07:00 ET
|
Krystal Biotech, Inc.; Jeune, Inc.
- Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections - Dr. Bhushan Hardas M.D., MBA appointed President, Jeune, Inc. PITTSBURGH, March 24,...
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
March 01, 2021 08:37 ET
|
Krystal Biotech, Inc.
- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21. - Today announced Positive Opinion from the European Medicines Agency on...
Krystal Biotech to Present at the Cowen 41st Annual Health Care Conference
February 23, 2021 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan,...
Krystal Biotech Announces Pricing of Upsized $125 Million Public Offering of Common Stock
February 02, 2021 20:51 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the...
Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Conferences
September 09, 2020 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus...
Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications
August 25, 2020 08:00 ET
|
Krystal Biotech, Inc.
KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection First in-human study will evaluate the safety and efficacy in acne scars and facial...
Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis
August 17, 2020 16:01 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector...
Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational Progress
August 10, 2020 08:00 ET
|
Krystal Biotech, Inc.
Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients Today announced enrollment of 1st patient in Phase 2 clinical study evaluating KB105 in ARCI patients On track to...
Krystal Biotech to Present at the William Blair BioTech Conference
July 30, 2020 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus...